SCHEMBL468830

SCHEMBL468830

CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB2 P05107 3/20 0.64
ICAM1 P05362 3/20 0.64
ITGAL P20701 3/20 0.64
CA1 P00915 3/20 0.57
CA2 P00918 3/20 0.57
SLC6A5 Q9Y345 1/20 0.57
CYP3A4 P08684 3/20 0.56
SLC7A5 Q01650 1/20 0.56
REN P00797 1/20 0.53
SLC15A2 Q16348 1/20 0.52
QPCT Q16769 1/20 0.51
QPCTL Q9NXS2 1/20 0.51
ACE2 Q9BYF1 1/20 0.51
ALDH1A1 P00352 2/20 0.49
EPHX2 P34913 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP2C19 P33261 1/20 0.49
AGTR2 P50052 1/20 0.49
GGT1 P19440 1/20 0.49
CPB2 Q96IY4 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15683044 1.00 ITGB2 (0.64) ITGB2ICAM1ITGALCA1CA2
SCHEMBL6026427 1.00 ITGB2 (0.64) ITGB2ICAM1ITGALCA1CA2
Water SCHEMBL8680774 0.98 ITGB2 (0.63) ITGB2ICAM1ITGALCA1CA2
SCHEMBL15080457 0.89 REN (0.54) ITGB2ICAM1ITGALCA1CA2
SCHEMBL9860623 0.89 ITGB2 (0.57) ITGB2ICAM1ITGALCA1CA2
SCHEMBL27413426 0.88 ITGB2 (0.67) ITGB2ICAM1ITGALCA1CA2
SCHEMBL18676311 0.86 SLC6A5 (0.59) ITGB2ICAM1ITGALCA1CA2
SCHEMBL21048720 0.86 ITGB2 (0.59) ITGB2ICAM1ITGALCA1CA2
SCHEMBL6806998 0.85 ITGB2 (0.62) ITGB2ICAM1ITGALCA1CA2
SCHEMBL5808674 0.85 HTR1D (0.51) ITGB2ICAM1ITGALCYP3A4SLC7A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 839 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3869192-B1 METHOD FOR QUANTITATIVE DETECTION OF VARIOUS METABOLITES IN BIOLOGICAL SAMPLE HUMAN METABOLOMICS INST INC (CN) 2026-05-13 EP claimed
US-20260091067-A1 METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES MARVELBIOME INC (US) 2026-04-02 US claimed
US-20260026495-A1 STABLE PLASMIN COMPOSITIONS FOR ORGAN PRESERVATION AND RECONDITIONING GRIFOLS WORLDWIDE OPERATIONS LTD (IE) 2026-01-29 US claimed
US-20250258146-A1 QUANTITATIVE DETECTION METHOD OF MULTIPLE METABOLITES IN BIOLOGICAL SAMPLE AND METABOLIC CHIP HUMAN METABOLOMICS INSTITUTE INC. (CN) 2025-08-14 US claimed
EP-4587116-A2 METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES MarvelBiome, Inc. (US) 2025-07-23 EP claimed
EP-3615069-B1 N-ACETYLATED AND NON-ACETYLATED DIPEPTIDES CONTAINING ARGININE TO REDUCE THE VISCOSITY OF VISCOUS COMPOSITIONS OF THERAPEUTIC POLYPEPTIDES AMGEN INC (US) 2025-05-28 EP claimed
WO-2025054048-A1 METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING LIPID AND CHOLESTEROL METABOLISM ASSOCIATED DISEASES, DISORDERS, AND CONDITIONS MarvelBiome, Inc. (US) 2025-03-13 WO claimed
CN-119584859-A Stable plasmin compositions for organ preservation and conditioning 基立福环球运营有限公司 2025-03-07 CN claimed
CN-114269951-B Diagnostic method for aesthetic deterioration of skin 欧莱雅 2024-12-27 CN claimed
CN-118406439-B Chemical mechanical polishing composition and application thereof in tungsten chemical mechanical polishing 万华化学集团电子材料有限公司 2024-10-18 CN claimed
EP-1344515-A1 SKIN COSMETICS Shu Uemura Cosmetics Inc. (JP) 2003-09-17 EP claimed
US-6524593-B1 Alleviate or improve various cosmetic conditions and dermatological disorders, skin, hair, nails TRISTRATA, INC. 2003-02-25 US claimed
US-6159485-A COSMETICS; SKIN DISORDERS YUGENIC LIMITED PARTNERSHIP (US) 2000-12-12 US claimed
WO-2000040217-B1 TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS YUGENIC LIMITED PARTNERSHIP (US) 2000-10-05 WO claimed
US-5925317-A Dual neutralization system for iodine treatment of contact lenses BAUSCH & LOMB INCORPORATED (US) 1999-07-20 US claimed
EP-0885019-A1 DUAL NEUTRALIZATION SYSTEM FOR IODINE TREATMENT OF CONTACT LENSES BAUSCH & LOMB INCORPORATED (US) 1998-12-23 EP claimed
EP-0433112-B1 Modified gangliosides and the functional derivatives thereof FIDIA SPA (IT) 1998-10-28 EP claimed
WO-1997026923-A1 DUAL NEUTRALIZATION SYSTEM FOR IODINE TREATMENT OF CONTACT LENSES BAUSCH & LOMB INCORPORATED (US) 1997-07-31 WO claimed
WO-1993002689-A1 SYNTHETIC RIBONUCLEASES AND METHODS FOR PREPARING AND USING SAME UNIVERSITY OF MEDICINE & DENTISTRY (US) 1993-02-18 WO claimed
EP-0433112-A1 Modified gangliosides and the functional derivatives thereof FIDIA S.p.A. (IT) 1991-06-19 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260026495-A1 STABLE PLASMIN COMPOSITIONS FOR ORGAN PRESERVATION AND RECONDITIONING PLG, PLPBP, F2 ITGB2 2426/4885ICAM1 3676/4885ITGAL 2293/4885
US-20260091067-A1 METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES IAPP, GPR119, FAHD1 ITGB2 2550/4885ICAM1 1885/4885ITGAL 3474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.